Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT06614465
Active, not recruiting Not applicable

Multimodal Rehabilitation Programme on Epigenetic Biomarkers, Quality of Life, Sexual Function and Muscle Strength in Women With Dyspareunia and Endometriosis.

NCT06614465 · tracked via the Priya Life Science Spain tracker
Sponsor
Clínica INEBIR
Phase
Not applicable
Started
2025-01-08
Last updated
2025-05-22

Condition(s) studied

Multidisciplinary Communication

Investigational drug(s) / intervention(s)

Multimodal Rehabilitation

Multimodal Rehabilitation: The intervention will consist of 4 sessions of education in pain neuroscience, 4 sessions of therapeutic exercise and 4 sessions of manual therapy in the abdominopelvic area.

Study summary

This study aims to evaluate the impact of a multimodal rehabilitation programme on epigenetic biomarkers in blood, quality of life, sexual function and pelvic floor muscle strength and endurance in women with dyspareunia and endometriosis.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Women diagnosed with endometriosis * Women with dyspareunia and chronic pelvic pain * Ability to communicate fluently verbally and in writing in the language of the research team, in this case Spanish. * Approval to participate in the study by your regular gynaecologist who is part of your diagnosis and treatment. Exclusion Criteria: * A neurological, oncological or autoimmune disease that prevents the participant from performing exercise. * Any type of pathology that prevents the participant from performing exercise. * A diagnosis of severe psychiatric or neurological disorders that do not allow the participant to follow orders.

Primary outcome measure(s)

  • miR-21 — 1 month
    miR-21 levels in saliva
  • Quality of life — 1 month
    will be measured with the The Short Form-36 Health Survey (SF-36). A higher score indicates better health status.
  • Sexual Function — 1 month
    Will be measured with the Female Sexual Function Index (FSFI) questionnaire. A higher score indicates better sexual function.
  • Pelvic Floor Muscle Strength — 1 month
    Will be measured with Oxford and Perfect scale. A higher score indicates better Muscle Strength status.
  • Pain — 1 month
    Will be measured with Brief Pain Inventory (BPI) Questionnaire. A higher score indicates worse health status.

Trial sites (1)

FacilityCityRegionStatus
Universidad Pablo de Olavide Seville Andalusia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06614465 on ClinicalTrials.gov ↗ ← All trials in Spain